Trial results

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

NCT06257966 on ClinicalTrials.gov · last registry update 2025-09-17

Closed to new participants; the 600 already enrolled are still being followed. Due to report 1 October 2026, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: HbA1c. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 17 July 2024 — 2 years so far. dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

ACTIVE_NOT_RECRUITING

Phase

P3

Drug

dulaglutide

Trulicity

Sponsor

Beijing Dongfang Biotech Co., Ltd.

Sponsor type

Industry

Enrollment

600

Started

2024-07-17

Primary completion

2026-10-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

HbA1c

Conditions studied

Type2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.